Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
 |
|
|
View more from the latest issues of:
|
|
|
|
|
 |
IN3 Conferences Partner Medtech Innovators with Top Investors & Corporate M&A Leaders
You spoke. We listened! IN3 is proud to introduce a completely new and improved conference format at IN3 Summit integrating Investor Day with the main program for a full, 3 days of start-up presentations, investor presentations, and key plenary/panel sessions. Network with numerous investment leaders, emerging medtech innovators, key service providers, and other important industry affiliates. IN3 Summit, Oct. 27-29, 2010, San Francisco. |
|
|
|
Upcoming Pharmaceutical Strategic Alliances Conference Session Focuses on the Direction of Pharma R & D
In this session, we’ll hear from Mark McClellan, the most creative administrator the FDA and CMS have ever had (indeed, the only person to ever serve at the top of both agencies), and who is now the force behind some of the most innovative changes in payer and customer buying behavior. We’ll then hear from Rob Epstein, Chief Medical Officer of Medco – who has spearheaded the largest private-customer research effort, a program which has already redefined the value of large clinical trials and almost singlehandedly blunted the launch of Lilly’s most important new drug.
Find out more… |
|
|
|
Biogen Idec, Takeda, Merck and Pfizer discuss Their Expansion Strategy at PharmAsia Summit 2010
From trends data to case studies on dealmaking Asia, find out how the best of the best strategic leaders are risk sharing and capitalizing on the Asia’s rewards. This year's conference brings the industry leaders in Asia to the U.S., to share their experiences and help you understand the myriad of challenges -- from regulatory, IP and pricing to capitalizing on partnering and investment opportunities.
Find out more… |
|
|
|
Therapeutic Area Partnerships Attracts In-licensors and Out-licensors from all the Major Pharma Companies Looking for Portfolio Growth Strategies
Merck, Astellas, Daiichi-Sankyo, Novo Nordisk, GSK, plus many more dealmakers in oncology, cardiovascular/metabolic, neuroscience, infectious diseases, inflammatory/autoimmune diseases and more are signed up to participate in one of the most exciting, targeted, partnering events of the year. All the major players will be there.
Find out more… |
|
|
|
Upcoming Elsevier Business Intelligence Webinars
|
Elsevier Business Intelligence Webinars have served more than 3,000 participants with insightful, thought-provoking and action-oriented discussions of our industry — straight from the minds of those in the know. |
 |
To learn more about Elsevier Business Intelligence Webinars and to register
click here.
|
|
|
|
Special Report: Bigger, Tougher, Faster:
Preparing for the New FDA
When Commissioner Margaret Hamburg promised to
beef up FDA regulatory authority, she wasn't kidding. New inspectors, tighter
manufacturing requirements and faster responses to violations — it's all headed
your way, and soon. What will all these freshly-trained inspectors be looking
for? How can you prepare for a smooth inspection? And what should you do when
the worst happens?
This Special Report answers all these questions and more, and gives you peace of mind ahead of any inspection, any time.
Click here for more information
and to order. |
|
 |
|
|
|
New ElsevierBI Search for ALL Pubs with Custom RSS NOW AVAILABLE!
The enhanced search enables you to search across all our publications and deals content in one search function. Interested in customizing your own RSS feeds? The new
RSS functionality allows you to access predefined RSS feeds via one simple click based on publication and topic as well as create new feeds based on your criteria so you can create alerts, or feed headlines onto a web site or intranet. Click on the
Advanced Search in the box above to begin your search or to subscribe any of our feeds now! |
|
|
|
Special Report: Oncology Outlook: How Cutting-Edge Medical Technology is Improving the Odds for Cancer Patients
With a huge and still growing population
vulnerable to breast, prostate and colon cancer, screening and treatment
represent an almost unlimited market. But some devices and diagnostics are the
wave of the future — including digital tomosynthesis imaging, partial breast
irradiation, virtual colonoscopy and HIFU (high-intensity focused ultrasound)
prostate treatment — while others are starting to suffer from their own
individual drawbacks. Where should you jump into the market? Who's already
there, and who's challenging the major players?
This Special Report answers all these questions and more with in-depth analysis of the potential market for everything from traditional radiation oncology to the leading-edge robotic radical prostatectomy diagnosis and treatment modalities.
Click here for more information
and to order. |
|
 |
|
|
|
|
|
 |
|
|
|
 |
|
 |
|
|
| |
 |
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs. . . [MORE] (IN VIVO)
Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. . . [MORE] (Start-Up)
Laser Cataract Surgery Comes into Focus at ASCRS
The mood was primarily upbeat at April's annual meeting of the American Society of Cataract and Refractive Surgery. Most in attendance expected a modest rebound in procedure volumes for 2010. . . [MORE] (Medtech Insight)
FDA, Drug Development and Health Care Reform: A Panel Discussion
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
